Search results
Merck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly Beat
Investor's Business Daily· 2 hours agoMerck noted that the devaluation of the Argentine peso had a 2% impact on sales. Minus that factor,...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 21 hours agoThe RS Rating is a 1-99 measure of a stock's 12-month performance. This means Moderna stock outranks...
U.S. regulators give full approval to Pfizer COVID-19 vaccine
AOL· 6 days agoThe U.S. gave full approval to Pfizer's COVID-19 vaccine on Monday, a milestone that may help lift public confidence in the shots as the nation battles ...
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 21 hours agoThe RS Rating measures a stock's 12-month running performance against all other stocks. That RS...
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for...
Morningstar· 3 days agoImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Designated ...
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks via Yahoo Finance· 3 hours agoBoosted...Consensus Estimate for 2024 EPS has declined from $11.13 per share to $11.12 over the past...
Why Is ImmunityBio Stock Trading Higher On Tuesday? - ImmunityBio (NASDAQ:IBRX)
Benzinga· 2 days agoThe drug is combined with the BCG vaccine, mainly used against tuberculosis and as a common treatment for some forms of bladder cancer. Last year in May, the FDA issued a ...
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Motley Fool via Yahoo Finance· 4 days agoThe 10 stocks that made the cut could produce monster returns in the coming years. Consider when...
Merck Raises 2024 Profit Forecast on Strong Sales of Cancer Drug Keytruda
US News & World Report· 5 hours agoThe New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous forecast of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year. Merck's ...
ImmunityBio stock jumps as FDA clears bladder cancer therapy (NASDAQ:IBRX)
Seeking Alpha· 2 days agoShares of ImmunityBio (IBRX) surged 33% premarket after FDA clearance of its combination therapy for...